News

Filter

Current filters:

Erbitux

1 to 9 of 385 results

Bristol-Myers Squibb gives full responsibility for Erbitux in Japan to Merck

Bristol-Myers Squibb gives full responsibility for Erbitux in Japan to Merck

13-02-2015

German pharmaceuticals and chemicals major Merck KGaA is to end the co-promotion of Erbitux (cetuximab)…

Bristol-Myers SquibbErbituxJapanLicensingMerck & CoOncologyPharmaceutical

Moderate growth forecast for colorectal cancer drug market

22-01-2015

The value of the colorectal cancer (CRC) therapeutics market will increase moderately, from $8.3 billion…

AvastinBayerBristol-Myers SquibbErbituxGlobalMarkets & MarketingMerck KGaAOncologyPharmaceuticalRocheStivarga

Erbitux equal to Avastin in colorectal cancer survival, FIRE-3 study shows

Erbitux equal to Avastin in colorectal cancer survival, FIRE-3 study shows

30-06-2014

Merck Serono, the biotech subsidiary of Germany’s Merck KGaA, has released positive new clinical trial…

AvastinBiotechnologyErbituxMerck KGaAMerck SeronoOncologyResearchRoche

Merck Serono’s Erbitux to be funded by CDF in England for mCRC

28-02-2014

The UK’s Cancer Drugs Fund (CDF) says that Erbitux (cetuximab) can be used in the first line setting…

ErbituxFinancialHealthcareMerck KGaAMerck SeronoNorthern EuropeOncologyPharmaceuticalUK

European Commission backs wider use of Merck’s Erbitux

European Commission backs wider use of Merck’s Erbitux

24-12-2013

Merck Serono, the biopharmaceutical division of Germany’s Merck KGaA, has gained European Commission…

ErbituxEuropeMerck KGaAMerck SeronoOncologyPharmaceuticalRegulation

Merck KGaA improves guidance with strong third quarter results

Merck KGaA improves guidance with strong third quarter results

14-11-2013

Germany’s Merck KGaA (MRK: DE) has posted solid organic revenue growth of 4.7% for the third quarter…

BiotechnologyErbituxEuropeFinancialMerck KGaAMerck SeronoPharmaceuticalRebif

1 to 9 of 385 results

COMPANY SPOTLIGHT

Menarini

Back to top